2/9/2016
`
`FiercePharma
`
`GSK readies 500 reps for Horizant launch - FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`GSK readies 500 reps for Horizant launch
`April 8, 2011 | By Tracy Staton
`
`SHARE
`
`Now that they have FDA approval for Horizant in the bag, GlaxoSmithKline and
`Xenoport are working out a sales strategy. And if the companies' statistics hold
`true, there are more than 5 million Americans with symptoms of restless legs
`syndrome, all potential buyers for this new treatment.
`
`TOOLS
`
`Comment
`
`Print
`
`Contact
`Author
`
`Reprint
`
`There's been plenty of debate about whether restless legs constitute a "real"
`syndrome and whether sufferers really need a drug. To combat those arguments,
`Xenoport has data suggesting the syndrome doesn't just consist of its trademark
`leg twitching and restless sleep, but may be linked to high blood pressure and
`heart disease. And the fact is, sufferers are seeking treatment.
`
`That's where Horizant comes in, beginning July 1, the companies say.
`GlaxoSmithKline will field a sales force of some 500 reps, Xenoport CEO Ron
`Barrett told FierceBiotech. Among their targets: The 60,000 to 70,000 primary care
`doctors and neurologists who now write most of the scrips for restless legs
`treatment.
`
`[Webinar] Physician Prescribing Trends & Opportunities for Health
`System-Pharma Collaboration
`
`DATE: WEDNESDAY, MARCH 16 | 11AM ET / 8AM PT
`athenahealth conducted a study to learn how health systems and new reimbursement models
`are impacting prescribing behavior. We'll discuss our findings, including opportunities for
`pharma marketers, with a health system leader on our March 16th webinar. Reserve Your Spot
`Today!
`
`Sign up for our FREE newsletter for more news like this sent to your inbox!
`
`Xenoport itself has the right to co-market the drug, but the company doesn't plan to
`do so right away, Barrett said. If it does decide to build up its own sales force, it
`would hire 50 to 100 reps to complement GSK's work. As Xconomy points out,
`Xenoport's share of profits varies according to how much it contributes to the
`partnership with GSK.
`
`- read the Xconomy story
`- get more from the Los Angeles Times
`
`Related Articles:
`XenoPort rockets up after FDA approves Horizant for RLS
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company
`news and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`EMAIL ADDRESS
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Doctors pounce on 'alarmist,' 'horrifying' Novartis
`heart-failure ad
`Top exec exits as Pfizer redraws org chart for post-
`megamerger future
`NICE, in reversal, OKs Amgen's Repatha while
`snubbing Sanofi and Regeneron's Praluent
`Some top GSK investors aren't sold on a breakup--
`and they're backing CEO Witty, too
`PhRMA kicks off new ad campaign to doctor
`pharma's tarred image
`
`THE LIBRARY: MULTIMEDIA
`FierceBiotech Radio on the burning hole in
`Gilead's $25B pocket and AbbVie's future in
`
`http://www.fiercepharma.com/story/gsk-readies-500-reps-horizant-launch/2011-04-08
`
`1/3
`
`Page 1 of 2
`
`SENJU EXHIBIT 2307
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`FiercePharma
`
`GSK readies 500 reps for Horizant launch - FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`GSK readies 500 reps for Horizant launch
`April 8, 2011 | By Tracy Staton
`
`SHARE
`
`Now that they have FDA approval for Horizant in the bag, GlaxoSmithKline and
`Xenoport are working out a sales strategy. And if the companies' statistics hold
`true, there are more than 5 million Americans with symptoms of restless legs
`syndrome, all potential buyers for this new treatment.
`
`TOOLS
`
`Comment
`
`
`Contact
`Author
`
`Reprint
`
`There's been plenty of debate about whether restless legs constitute a "real"
`syndrome and whether sufferers really need a drug. To combat those arguments,
`Xenoport has data suggesting the syndrome doesn't just consist of its trademark
`leg twitching and restless sleep, but may be linked to high blood pressure and
`heart disease. And the fact is, sufferers are seeking treatment.
`
`That's where Horizant comes in, beginning July 1, the companies say.
`GlaxoSmithKline will field a sales force of some 500 reps, Xenoport CEO Ron
`Barrett told FierceBiotech. Among their targets: The 60,000 to 70,000 primary care
`doctors and neurologists who now write most of the scrips for restless legs
`treatment.
`
`[Webinar] Physician Prescribing Trends & Opportunities for Health
`System-Pharma Collaboration
`
`DATE: WEDNESDAY, MARCH 16 | 11AM ET / 8AM PT
`athenahealth conducted a study to learn how health systems and new reimbursement models
`are impacting prescribing behavior. We'll discuss our findings, including opportunities for
`pharma marketers, with a health system leader on our March 16th webinar. Reserve Your Spot
`Today!
`
`Sign up for our FREE newsletter for more news like this sent to your inbox!
`
`Xenoport itself has the right to co-market the drug, but the company doesn't plan to
`do so right away, Barrett said. If it does decide to build up its own sales force, it
`would hire 50 to 100 reps to complement GSK's work. As Xconomy points out,
`Xenoport's share of profits varies according to how much it contributes to the
`partnership with GSK.
`
`- read the Xconomy story
`- get more from the Los Angeles Times
`
`Related Articles:
`XenoPort rockets up after FDA approves Horizant for RLS
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company
`news and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`EMAIL ADDRESS
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Doctors pounce on 'alarmist,' 'horrifying' Novartis
`heart-failure ad
`Top exec exits as Pfizer redraws org chart for post-
`megamerger future
`NICE, in reversal, OKs Amgen's Repatha while
`snubbing Sanofi and Regeneron's Praluent
`Some top GSK investors aren't sold on a breakup--
`and they're backing CEO Witty, too
`PhRMA kicks off new ad campaign to doctor
`pharma's tarred image
`
`THE LIBRARY: MULTIMEDIA
`FierceBiotech Radio on the burning hole in
`Gilead's $25B pocket and AbbVie's future in
`
`http://www.fiercepharma.com/story/gsk-readies-500-reps-horizant-launch/2011-04-08
`
`1/3
`
`Page 1 of 2
`
`SENJU EXHIBIT 2307
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`2/9/2016
`
`GSK, XenoPort revise Horizant pact
`
`GSK readies 500 reps for Horizant launch - FiercePharma
`hematology
`
`EMAIL ADDRESS
`
`Filed Under GlaxoSmithKline, Horizant, Pharma sales reps, Restless Leg Syndrome, Xenoport
`
`COMMENTS
`
`Sponsored
`FISHER INVESTMENTS
`I HATE Annuities...and So Should You!
`If you have a $500,000 portfolio, uncover the truth about annuities
`by reading "Annuity Insights" from Forbes columnist Ken Fisher's
`firm.
`
`Learn More
`
`1 Comment
`
`FiercePharma
`
`
`
`Recommend
`
`Share⤤
`
`Join the discussion…
`
`| DECEMBER 10, 2015
`
`FiercePharma's Carly Helfand and
`FierceBiotech's Damian Garde
`discuss the discussion around Gilead
`Sciences' huge cash reserve and the many
`things the company might buy. Plus, a look
`back at AbbVie's blockbuster buyout of
`Pharmacyclics and a consideration of how a
`certain biotech entrepreneur is bringing
`attention to an FDA loophole.
`
`MORE ITEMS
`
`1
`
`Login
`
`Sortr by Best
`
`LATEST COMMENTARY
`
`AstraZeneca chief chalks up milestones on his map
`to $45B
`What's the calendar bringing biopharma next year?
`Our top 5 ideas
`The most popular FiercePharma stories of 2015
`Does new scrutiny threaten pharma's specialty-
`pharmacy strategy?
`Pfizer responds to FiercePharma
`
`Anonymous • 5 years ago
`I can assure you RLS is a documented medical condition. I have had it since the age of
`12. As I age there have been times it has been so unbearable I have gone for weeks
`on an hour or two of sleep per night. When I was put on mirapex my sleep improved
`100%. The problem is, with time, mirapex becomes less effective.
`• Reply •
`Sharerr
`›
`△ ▽
`
`✉
`
`Subscribe
`
`d
`
`Add Disqus to your site Add Disqus Add
`
`(cid:32)
`
`Privacy
`
`EVENTS
`Drug Development Immersion Course
`Course | May 17-18, 2016 — West Windsor
`(Princeton area), NJ — Sponsored By:
`FierceBiotech
`
`CBI's Global Anti-Corruption and FCPA
`Compliance Congress
`March 16-17, 2016 — Philadelphia, PA
`
`Exl's 2nd Procurement and Outsourcing
`Summit
`March 22-23, 2016 — The Inn at Penn, A
`Hilton Hotel — Philadelphia, PA
`MORE EVENTS
`
`
`
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`PRESS RELEASES
`Immunovia announces collaboration with Mount Sinai Health System to
`validate early detection blood test for pancreatic cancer in a prospective
`clinical study
`First patient treated with LC Bead LUMI™ radiopaque embolic bead
`supported by Philips live image guidance
`Amplyx Pharmaceuticals Expands Management Team and Increases Its
`Series B Financing to $49.2 Million
`SANOFI DELIVERED 2015 BUSINESS EPS UP 8.5% ON A REPORTED
`BASIS AND STABLE AT CONSTANT EXCHANGE RATES CONSISTENT
`WITH GUIDANCE
`CMS will cover percutaneous LAAC therapy for Medicare beneficiaries
`consistent with the FDA label when specific conditions are met
`
`http://www.fiercepharma.com/story/gsk-readies-500-reps-horizant-launch/2011-04-08
`
`2/3
`
`Page 2 of 2
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
